11 March 2024
EMA/585020/2023
EMEA/H/C/005754

Public statement

VidPrevtyn Beta (SARS-CoV-2, B.1.351 variant, prefusion Spike delta TM protein, recombinant)

Withdrawal of the marketing authorisation in the European Union

On 11 March 2024, the European Commission withdrew the marketing authorisation for VidPrevtyn Beta (SARS-CoV-2, B.1.351 variant, prefusion Spike delta TM protein, recombinant) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sanofi Pasteur, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

VidPrevtyn Beta was granted marketing authorisation in the EU on 10 November 2022 for active immunisation against coronavirus disease 2019 (COVID-19). The marketing authorisation was initially valid for a 5-year period.

The European Public Assessment Report (EPAR) for VidPrevtyn Beta will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged.